Physician profile
C Hood
NPI 1356360689
$1,107.41
in general payments reported to CMS, 2019-2025
15 companies · $437 in 2025
The $437 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $117 · 2023: $160 · 2024: $393 · 2025: $437.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $990.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $990.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $160.84 | 2022-2024 | |
| Alkermes, INC. | $148.45 | 2022-2025 | Vivitrol |
| Phathom Pharmaceuticals, INC. | $129.97 | 2025 | Voquezna |
| Otsuka America Pharmaceutical, INC. | $125.00 | 2025 | Rexulti |
| Amgen INC. | $120.58 | 2024 | Repatha |
| Alexion Pharmaceuticals, INC. | $91.12 | 2024 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $69.01 | 2024-2025 | Caplyta |
| Supernus Pharmaceuticals, INC. | $64.27 | 2023-2025 | Qelbree, Qelbree |
| Astrazeneca Pharmaceuticals LP | $60.90 | 2025 | Breztri, Airsupra |
| Lundbeck LLC | $31.07 | 2023-2024 | Rexulti |
| Globus Medical, INC. | $26.70 | 2025 | Senza |
| Braeburn INC. | $23.41 | 2024 | Brixadi |
| Abbott Laboratories | $22.32 | 2024 | Freestyle Libre 3 |
| Exact Sciences Corporation | $19.66 | 2025 | The Cologuard Plus Collection Kit |
| Novo Nordisk INC | $14.11 | 2025 | Wegovy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw C Hood listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.